Empyrean Diagnostics Inc.
This article was originally published in The Gray Sheet
Executive SummaryAgrees with Rilldale Ltd. of London, England, to share ownership of a new Swiss company with a 99-year license to manufacture and distribute EDI's proprietary HIV-1 test kit in Western Europe and Turkey. Rilldale, which "has committed a minimum of $2 mil." to the new company, will bear all start-up costs and oversee day-to- day operations. Empyrean, a U.S. subsidiary of Vancouver, British Columbia-based Socal Capital ("The Gray Sheet" Oct. 19, p. 9), will receive royalties on a per-item basis from the new firm, will receive a percentage of its gross sales, and will split the new company's net profits with Rilldale. Empyrean President and CEO Daniel Bland "is confident" that the Swiss firm will sell 25 million test kits at roughly $1.50 per kit by the end of 1994.
You may also be interested in...
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.